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Abstract 20 
Renal cell carcinoma (RCC) denotes cancer originated from renal epithelium and accounts for >90% of 21 
cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear 22 
cell RCC (ccRCC) is most common and accounts for most cancer-related deaths. Although somatic VHL 23 
mutations have been described for some time, more-recent cancer genomic studies have identified 24 
mutations in epigenetics regulatory genes and demonstrated marked intratumour heterogeneity, which 25 
could have prognostic, predictive and therapeutic relevance. Localized RCC can be successfully managed 26 
with surgery whereas metastatic RCC is refractory to conventional chemotherapy. However, over the past 27 
decade, marked advances in treatment of metastatic RCC have been made, with targeted agents including 28 
sorafenib, sunitinib, bevacizumab, pazopanib and axitini that inhibit vascular endothelial growth factor 29 
(VEGF) and its receptor(VEGFR) and everolimus and temsirolimus, which inhibit mTOR complex 1, being 30 
approved. Since 2015, agents with additional targets aside from VEGFR have been approved, such as 31 
cabozantinib and lenvatinib; immunotherapies such as nivolumab have also been added to the 32 
armamentarium for metastatic RCC. Here, we provide an overview of the molecular biology of RCC, with 33 
  2 
a focus on ccRCC, as well as updates to complement current clinical guidelines and an outline of potential 34 
future directions for RCC research and therapy. 35 
 36 
[H1] Introduction  37 
Renal cell carcinoma (RCC) encompasses a heterogeneous group of cancers derived from renal tubular 38 
epithelial cells1 and is among the 10 most common cancers worldwide. Key advances in histopathological 39 
and molecular characterization of RCC over the past two decades have led to major revisions in its 40 
classification2-5. Major subtypes6 with ≥5% incidence are clear cell RCC (ccRCC)7, papillary RCC (pRCC)8 41 
and chromophobe RCC (chRCC)9 (FIG. 1). The remaining subtypes are very rare (each with ≤1% total 42 
incidence)5 and in cases where a tumour does not fit any subtype diagnostic criteria, it is designated as 43 
unclassified RCC (uRCC, ~4% total incidence)10. ccRCC is the most common subtype and accounts for the 44 
majority of kidney cancer deaths and is the focus of this Primer11. Indeed, owing to the predominance of 45 
clear cell histology in metastatic disease (83-88%)12,13, tumours with non-clear cell histology have been 46 
grouped as ‘nccRCC’ (Table 1) for feasibility in conducting clinical trials14-16. Furthermore, recent cancer 47 
genomic studies have revealed an overt complexity of intra-tumour17-19 and inter-tumour7,20 heterogeneity 48 
in ccRCC, which could contribute to the heterogeneous clinical outcomes observed21-23.   49 
 50 
Localized RCC can be treated with partial or radical nephrectomy (removal of the kidney)24, ablation25 51 
(destruction of the malignant tissue with heat or cold) or active surveillance26 (monitoring of tumour 52 
growth with periodic radiographic studies). Despite nephrectomy with curative intent, ~30% of patients 53 
with ccRCC with localized disease eventually develop metastases27-30, which require systemic therapies and 54 
is associated with high mortality. Targeted therapy against vascular endothelial growth factor (VEGF) and 55 
mTOR pathways have been developed, but treatment response is varied and most patients eventually 56 
progress31. However, increased genomic and molecular understanding of metastatic ccRCC has contributed 57 
to an unprecedented number of drugs approvals in the United States and European Union (currently 12 58 
approved drugs with six different effective mechanisms of action are approved). In this Primer, we discuss 59 
these new approvals and the major progress made in biology of ccRCC that led to their development. 60 
Furthermore, we present insights into genomics-based risk and treatment stratification and discuss 61 
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treatment sequencing and combinations that are paving the way for the future design of personalized 62 
clinical management plans. 63 
  64 
[H1] Epidemiology 65 
[H2] Incidence and mortality  66 
Kidney cancer accounts for approximately 2% of all cancer diagnoses and cancer deaths worldwide, with 67 
incidence rates generally higher in developed countries (FIG. 2)32. Annually, ~295,000 new kidney cancer 68 
cases are diagnosed and ~134,000 deaths are recorded worldwide33,34. Kidney cancer accounts for ~63,000 69 
new cases and ~14,000 deaths yearly in the United States35, and for ~84,000 new cases and ~35,000 deaths 70 
in Europe36. Men are more affected than women (a 2:1 ratio of new diagnoses). 71 
 72 
The median age of patients with RCC in the Surveillance, Epidemiology, and End Results (SEER) database 73 
in the United States was 64 years with a near normal distribution37. Accordingly, when RCC is diagnosed at 74 
younger ages (≤46 years, which represents the lowest decile of the age distribution)37,38, the possibility of 75 
an underlying hereditary kidney cancer syndrome — which accounts for 3-5% of all RCCs5 — should be 76 
considered (Table 2)39,40.  77 
 78 
The incidence of RCC highest in the Czech Republic, with age-standardized annual rates of 22.1 and 9.9 79 
new cases per 100,000 men and women, respectively, over the period 2003-200741. The incidence is also 80 
very high in the Baltic and Eastern European countries, although the reasons for this excess are not known. 81 
Overall, incidence rates have been increasing over time in most populations, but mortality rates have 82 
levelled off or are decreasing since 1990s. This divergent pattern of increasing incidence and decreasing 83 
mortality is particularly evident in developed countries. For example, analyses within the SEER database 84 
indicate that the increase in RCC incidence is confined to small and localized tumours, likely due at least in 85 
part to increasingly frequent incidental detection of small renal masses (tumours ≤4 cm in size) that are 86 
unlikely to have metastasized from increased use of abdominal imaging42. The global increases in the 87 
prevalence of obesity, an established RCC risk factor, might also play a part in increasing incidence, as 88 
well as influencing clinical outcome41,43.  89 
 90 
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[H2] Risk factors 91 
RCC incidence increases markedly with age and is higher for men than women. In the United States, 92 
incidence varies by ethnic group, with rates highest among Native American, Indigenous Alaskans and 93 
African Americans, and lowest among Asian Americans and people of Pacific Island descent35. The major 94 
established risk factors for RCC include excess body weight, hypertension and cigarette smoking44, which 95 
were factors in approximately half of all diagnosed cases in one US study45. Other medical conditions that 96 
have been associated with RCC in epidemiological studies include chronic kidney disease, haemodialysis, 97 
kidney transplantation, acquired kidney cystic disease, a previous RCC diagnosis and, possibly, diabetes 98 
mellitus44. Many lifestyle, dietary, occupational and environmental factors have also been associated with 99 
RCC with varying levels of evidence46. 100 
  101 
For example, contradictory reports exist on the association between red meat consumption and RCC 102 
risk47,48. Moderate alcohol consumption (≥11g per day) seems to reduce the risk for RCC48,49. In a case–103 
control study on physical activity and the risk of RCC, inverse trends in risk were found, and the authors 104 
concluded that 9% of RCC cases could be avoided by increasing physical activity50. However, the inverse 105 
association might have involved other confounding factors such as BMI and social class correlates. Other 106 
studies have found no such inverse association51.  107 
  108 
Genetic factors also contribute to RCC risk, as evidenced by individuals with a family history of renal 109 
cancer having an approximate twofold increased risk52. Investigations into familial RCC have uncovered 110 
mutations in at least 11 genes (namely BAP1, FLCN, FH, MET, PTEN, SDHB, SDHC, SDHD, TSC1, 111 
TSC2, and VHL), some of which have also been implicated in sporadic RCC development39. A notable 112 
example is VHL, the mutated gene underlying von Hippel-Lindau disease, which is characterized by a high 113 
risk of developing ccRCC53; inactivation of the VHL protein, leading to unchecked expression of 114 
oncogenic hypoxia-inducible factors (HIF-1 and HIF-2), is also a hallmark of sporadic ccRCC tumours (see 115 
Mechanisms, below)39,54. Genome-wide association studies (GWAS) of RCC have identified six 116 
susceptibility loci to date, on chromosome regions 2p21, 2q22.3, 8q24.21, 11q13.3, 12p11.23 and 117 
12q24.3155-58. The 2p21 locus maps to EPAS1, a gene encoding the HIF-2α subunit 55 whereas the 118 
biological effects underlying the 11q13.3 locus seems to be attributable to changes in the regulation of 119 
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CCND1 (encoding cyclin D1, which is involved in cell cycle regulation)59. The locus 12p11.23 probably 120 
maps to changes in BHLHE41 (encoding basic helix-loop-helix family member e41, which is thought to 121 
have a role in regulation of the circadian rhythm)60. The disease genes underlying the other GWAS 122 
susceptibility loci have yet to be identified. 123 
 124 
[H1] Mechanisms/pathophysiology 125 
[H2] Genes and pathways 126 
In ccRCC, the VHL tumour suppressor gene is the most frequently mutated gene7,54, and its complete loss 127 
through genetic (point mutations, indels and 3p25 loss) and/or epigenetic (promoter methylation) 128 
mechanisms constitutes the earliest, truncal oncogenic driving event61,62. VHL is the substrate recognition 129 
component of an E3 ligase complex that ubiquitinates HIF-1α and HIF-2α for proteasome-mediated 130 
degradation53,63,64. Loss of VHL, therefore, leads to aberrant accumulation of HIF proteins despite an 131 
adequately oxygenated tissue microenvironment, which in turn results in uncontrolled activation of HIF 132 
target genes that regulate angiogenesis, glycolysis and apoptosis (FIG. 3). Accordingly, human ccRCC 133 
tumours are rich in lipids and glycogens, and are highly vascular65,66 — which underlies why agents that 134 
primarily inhibit VEGF and its receptor VEGFR are effective treatments for metastatic ccRCC14,15,67. 135 
However, VHL loss alone is insufficient to induce ccRCC as evidenced by the long latency (>30 years) in 136 
individuals who harbour VHL germline mutations to develop ccRCC53 and by the observation that Vhl loss 137 
in mice is unable to induce ccRCC68. These results suggest that additional genetic and/or epigenetic events 138 
are probably needed for ccRCC to develop69.  139 
  140 
To identify these events, large-scale cancer genomic projects have been undertaken, and have revealed 141 
several novel prevalent mutations in ccRCC, including PBRM1 (29-41% of tumour samples), SETD2 (8-142 
12%), BAP1 (6-10%), KDM5C (4-7%) and MTOR (5-6%)7,70-73. Interestingly, PBRM1, SETD2 and BAP1 143 
encode chromatin and histone regulating proteins, are located at 3p21 and function as tumour 144 
suppressors7,70-72. As VHL resides at 3p25, a single copy loss of the short arm of chromosome 3 (3p) would 145 
result in haploinsufficiency of these four tumour suppressor genes, corroborating the fact that 3p loss (that 146 
is, loss of heterozygosity) is nearly a universal event in ccRCC61 and constitutes an early genetic event69. 147 
By contrast, MTOR mutations in ccRCC are generally missense and functionally activating73,74, which 148 
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could explain the reason mTOR pathway inhibitors, including everolimus and temsirolimus, are 149 
effective75,76.  150 
  151 
How individual mutations and their interactions contribute to the pathogenesis and their values as 152 
prognostic or predictive biomarkers in ccRCC are largely unknown. Nevertheless, a few studies have 153 
demonstrated interesting clinical correlations that warrant future validation. As inactivation of VHL is the 154 
founding event of ccRCC, its mutation status has no effect on clinical outcome, whereas mutations 155 
involved in disease progression such as PBRM1, SETD2 and BAP1 as well as KDM5C (which is also 156 
involved in chromatin modification) were shown to associate with aggressive clinical features77-79. Small 157 
renal masses harbouring PBRM1 mutations were associated with stage III pathological features (that is, 158 
extrarenal growth but not extending beyond Gerota’s fascia see below)71, whereas BAP1 mutations were 159 
associated with larger tumour sizes, higher Fuhrman nuclear grade (large nucleus with prominent 160 
nucleolus) and worse cancer-specific survival77,78,80. Interestingly, mutations in BAP1 and PBRM170 or 161 
KDM5C20 seem to occur mutually exclusively in ccRCC, offering a molecular subclassification of ccRCC. 162 
Furthermore, mutations of KDM5C, which is located at Xp.11, were predominantly detected in male 163 
patients and correlated with long-term therapeutic benefit from sunitinib20; and mutations of SETD2 were 164 
associated with reduced relapse-free survival80. 165 
 166 
[H2] Tumour heterogeneity and cancer evolution 167 
As Nowell first described 40 years ago81, genetic diversity within tumours is thought to provide the 168 
substrate upon which selection can act, to enable tumours to adapt to new microenvironmental pressures 169 
and metabolic demands during the natural history of the cancer (FIG. 4A). Such genetic diversity has been 170 
studied extensively in ccRCC. For example, in a study of four patients with ccRCC who had multiple 171 
tumours were subjected to multi-region genetic analysis, VHL mutation and 3p loss of heterozygosity were 172 
found to be ubiquitous events across all regions sampled17. By contrast, common driver events such as 173 
SETD2, PBRM1, MTOR, PIK3CA, PTEN and KDM5C mutations were present heterogeneously within the 174 
primary tumour and metastatic sites — in some regions but not others. Such genetic characteristics enable 175 
the construction of tumour phylogenies, whereby the ‘trunk’ of the evolutionary tree depicts mutations 176 
found in the most recent common ancestor (MRCA) that are present in every tumour cell. ‘Branched’ 177 
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mutations are found in some subclones but not others; these mutations may be regionally distributed across 178 
the tumour, occupying distinct regional niches within the primary tumour or different niches between the 179 
primary and metastatic sites of disease.  180 
 181 
Furthermore, parallel evolution has also been observed, whereby recurrent branch alterations in subclones 182 
affect the same gene, signal transduction pathway or protein complex (FIG. 4B). In some cases — such as 183 
BAP1, PBRM1 and SETD2 mutations — such recurrent but distinct alterations can be readily explained as 184 
the ‘second hit’ event in the evolution of the tumour. In other cases, parallel evolution suggests 185 
considerable selection pressures for disruption of the same signalling pathway or protein complex. 186 
Additionally, convergence of genetic characteristics has been noted in several studies of ccRCC19,23,82, 187 
whereby mutations in genes occur at different time points but result in similar overall genomic and 188 
phenotypic profiles; a ‘braided river’ model has been conceived to illustrate this phenomenon (FIG. 4C)69. 189 
Regardless of the modality, a follow up study of ccRCC samples for eight patients demonstrated evidence 190 
for branched evolution in which 73-75% of driver alterations were found to be subclonal18.  191 
 192 
Multi-region tumour analyses suggest the intriguing possibility that evolutionary trajectories are 193 
remarkably constrained in ccRCC, which — as our knowledge of microenvironmental, therapeutic and host 194 
selection pressures grows — could render the evolutionary routes predictable and, therefore, therapeutically 195 
tractable. For example, it has been shown that patients who responded well to mTOR inhibition harbour 196 
recurrent regionally separated aberrations in components of the mTOR pathway75. Furthermore, some 197 
subclonal alterations might be involved in the initiation and maintenance of cell-to-cell variation necessary 198 
for clonal selection. For example, SETD2 loss of function has been shown to impair nucleosome 199 
compaction, minichromosome maintenance complex component 7 (MCM7) function and DNA polymerase 200 
delta loading to chromatin, resulting in impaired DNA replication fork progression. Additionally, failure to 201 
load lens epithelium-derived growth factor p75 splice variant (LEDGF) and DNA repair protein RAD51 202 
homolog 1 (RAD51) — which are involved in DNA break repair — has also been observed upon SETD2 203 
loss, resulting in homologous recombination repair deficiency83. These events are, accordingly, plausible 204 
genomic biomarkers in ccRCC dispersed within distinct regional niches within each tumour19,84.  205 
 206 
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[H2] Immune infiltration and the tumour microenvironment 207 
In addition to genetic alterations, gene expression, metabolic and immunological analyses of ccRCC have 208 
also yielded important mechanistic and clinical insights 20,85-87. Of these, perhaps the immune infiltration 209 
characteristics of ccRCC is of increasing interest, given the rise of immune checkpoint-blocking therapies 210 
in this disease (see below, Management). Notably, among 19 cancer types examined by The Cancer 211 
Genome Atlas research programme, ccRCC has the highest T cell infiltration score 87. Furthermore, higher 212 
nuclear grade and stage in ccRCC was correlated with an increase in T helper 2 and T regulatory cell 213 
infiltration
87,88
.  214 
 215 
 216 
[H2] Disease models 217 
Although RCC cell lines have been used for mechanistic studies, 89 ccRCC tumours in patients are highly 218 
vascular — a feature that cannot be recapitulated with in vitro cell studies. Furthermore, such cell lines can 219 
acquire additional genetic and/or epigenetic changes during passages such that in vitro drug screens do not 220 
yield specific, translatable insights90. Nevertheless, when these cell lines were injected subcutaneously into 221 
laboratory animals, xenografted tumours largely respond to anti-VEGF therapy91 and can be used to 222 
investigate resistance mechanisms92,93.  223 
 224 
More recently, patient-derived xenograft (PDX) models have been established and have been shown to 225 
recapitulate the patient’s documented clinical response to targeted therapies, which could be used in pre-226 
clinical drug trials94. At the same time, efforts to develop mouse models that truly reflect human ccRCC 227 
genomics and morphology have been hampered by the fact that homozygous inactivation of the Vhl gene in 228 
mice does not result in ccRCC68. However, the identification of additional recurrent, prevalent mutations in 229 
human ccRCC have rekindled efforts to generate such models. For example, homozygous deletion of Vhl 230 
and Pbrm1 in a mouse model resulted in multifocal, lipid-rich, glycogen-rich, transplantable ccRCC (J.J.H., 231 
unpublished data). Interestingly, homozygous deletion of Vhl and Bap1 in a mouse model resulted in early 232 
lethality (<1 month), and some mice (within a cohort of 7) carrying homozygous deletion of Vhl and 233 
heterozygous deletion of Bap1 developed tumour micronodules (0.25-1.8mm) with unknown tumour 234 
incidence and molecular characteristics 95. Overall, animal models of RCC are currently limited but being 235 
eagerly pursued.  236 
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 237 
[H1] Diagnosis, screening and prevention 238 
[H2] Diagnosis  239 
Historically, patients were diagnosed with RCC after presenting with flank pain, gross haematuria and a 240 
palpable abdominal mass. Nowadays, the majority of diagnoses result from incidental findings. This shift is 241 
a consequence of the widespread use of non-invasive radiological techniques such as ultrasonography or 242 
abdominal CT imaging performed for another reason. That being said, paraneoplasic syndromes — 243 
symptoms caused by hormones or cytokines excreted by tumour cells or by an immune response against the 244 
tumour — are not uncommon in RCC 96 and symptoms include hypercalcaemia, fever and erythrocytosis. 245 
Most of these symptoms are usually reversed after tumour resection11. Diagnosis is usually strongly 246 
suspected by imaging studies although RCCs can display variable radiographic appearances97. Typical 247 
radiological features for ccRCC include exophytic (outward) growth, heterogeneity due to intratumoral 248 
necrosis or haemorrhage and high uptake of contrast-enhancement agents98.  249 
 250 
[H3] Staging.  251 
The stage of RCC reflects the tumour size, extent of invasion outside of the kidney, the involvement of 252 
lymph nodes and whether the tumour has metastasized (FIG. 5). CT imaging with contrast enhancement of 253 
the chest, abdominal cavity and pelvis is required for optimal staging. Such imaging enables assessment of 254 
primary tumour (size and whether the tumour is organ-confined or extends to perinephric fat or kidney 255 
hilum), regional spread (lymph node involvement) and distant metastases (lung, bone and distant lymph 256 
nodes). MRI can also provide additional information, especially to determine whether the tumour extends 257 
into the vasculature (vena cava tumour thrombus). Bone scan, 18F-fluorodeoxyglucose PET and imaging of 258 
the brain are not systematically recommended for initial staging14,15. Prognostic assessment will require 259 
further laboratory testing that includes, but is not limited to, haemoglobin, leukocyte and platelet counts; 260 
serum-corrected calcium levels; and lactate dehydrogenase levels99,100. 261 
  262 
[H3] Genomic implications.  263 
An age of onset of ≤46 years raises the possibility of a hereditary syndrome (Table 2) and, according to the 264 
American Society of Clinical Oncology, should trigger consideration for genetic counselling and might 265 
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serve as a useful cut-off age when establishing genetic testing guidelines37. Indeed, awareness of the non-266 
renal malignancies and non-neoplastic features associated with RCC is of interest to the physician to 267 
identify hereditary syndromes40. Furthermore, specific therapeutic options driven by the underlying biology 268 
are now being developed for these different RCC related to cancer susceptibility syndromes101. Upon 269 
confirmation, patients and their families harbouring mutations are subject to specialized monitoring and 270 
treatment plans to minimize morbidity and prevent mortality.  271 
  272 
[H2] Histopathological confirmation 273 
Histopathological confirmation of malignancy is obtained either with renal core biopsy or on the partial or 274 
radical nephrectomy specimen. Initial biopsy is recommended before ablative therapy is undertaken (in 275 
those for whom surgery is not an option) or before initiating systemic therapy (in those who have metastatic 276 
disease)102. In 2016, the WHO classification of RCC was updated5 from previous (2004) WHO1 and 277 
International Society of Urological Pathology (ISUP) Consensus Conference4 (2013) systems. Although 278 
most RCCs can be easily classified on the basis of histological criteria, some tumours pose a diagnostic 279 
problem because they display a combination of features characteristic of different subtypes. For instance, 280 
the presence of clear cells is not unique to ccRCC but can be observed in pRCC, chRCC and MiT family 281 
translocation RCC (tRCC)66. Similarly, papillary structures, characteristic of pRCC, can be present in other 282 
RCC types103. In challenging cases, careful evaluation of cytological features, growth pattern, 283 
immunophenotype and genetic alterations usually enables the proper diagnosis. However, a subset of RCCs 284 
(~4%) cannot be assigned to any specific category because they either present combined morphologies or 285 
display unusual features and are, therefore, designated uRCC3,104,105. Nevertheless, a recent molecular 286 
characterization of 62 aggressive uRCC revealed distinct subsets including NF2 loss (26%), mTORC1 287 
pathway activation (21%) and mutations in chromatin and DNA damage regulators (21%)10. 288 
 289 
At macroscopic examination, the cut surface of the ccRCC tumours is golden yellow with frequent 290 
haemorrhagic, necrotic and cystic areas. Microscopically, ccRCC usually consists of tumour cells with 291 
clear cytoplasm arranged in nests or tubules surrounded by a rich vascular network. The clear appearance 292 
of the cytoplasm is due to the accumulation of glycogen and lipids. A variable proportion of tumour cells 293 
with granular eosinophilic cytoplasm can be observed and, in some cases, these cells constitute the entire 294 
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tumour mass3,104,105. The most widely used grading system for ccRCC is the Fuhrman grading system, 295 
which defines four nuclear grades (1-4) in order of increasing nuclear size, irregularity and nucleolar 296 
prominence106. The Fuhrman nuclear grade has been shown to have prognostic value in ccRCC30,107,108. 297 
 298 
It should be noted that all RCC types can contain foci of high-grade malignant spindle cells (that is, 299 
sarcomatoid differentiation). Thus, sarcomatoid RCC is no longer considered as an entity but rather as a 300 
progression of any RCC type109. Of note, recent genomic insights from sequencing matched sarcomatous 301 
and carcinomatous RCC demonstrated enrichment in TP53 and CDKN2A mutations, implicating these 302 
genetic defects as underlying causes of sarcomatoid differentiation in RCC110-112.  303 
 304 
[H2] Screening 305 
Owing to the relatively low incidence of RCC, universal screening (such as that for asymptomatic micro-306 
hematuria) has not demonstrated a positive effect on outcomes in RCC113. Furthermore, other biomarkers 307 
have not yet been established for screening114,115. Imaging remains the primary tool for RCC detection and 308 
screening. An ultrasonography screening study in 45,905 participants reported a 10-fold higher RCC-309 
incidence than expected for a general population with improved cancer-free survival when compared with 310 
symptomatic patients116.  311 
 312 
Although most cases are sporadic62, the majority of patients with RCC might have a genetic 313 
predisposition38,117. Although, no guideline is available regarding the selection of patients for germline 314 
mutation testing, guidelines for monitoring those with confirmed hereditary syndromes that increase the 315 
risk of RCC are available37.  316 
 317 
[H2] Prevention: modifiable risk factors 318 
Smoking, obesity and hypertension are associated with increased risks of developing RCC whereas 319 
exercise and moderate consumption of alcohol and flavonoids reduce RCC risks.  320 
 321 
[H3] Tobacco. When compared to never smokers, a relative risk for ever smokers of 1.38 (95%CI=1.27-322 
1.50) was reported in a meta-analysis including 8,032 cases and 13,800 controls from 5 cohort studies118. A 323 
  12 
dose-dependent increase in risk in both men and women was found; individuals who had quit smoking >10 324 
years prior had a lower risk when compared to those who had quit <10 years prior. Other studies have 325 
confirmed smoking as a risk factor for RCC119. 326 
 327 
[H3] Obesity. A 5 kg/m2 increase in body mass index (BMI) was found to be strongly associated with 328 
RCC120. Similarly, a strong association between weight gain in early and mid-adulthood (18–35 years of 329 
age) with RCC was reported121. Moreover, central adiposity (relative risk 1.8, 95%CI 1.2-2.5) and the 330 
waist-to-hip ratio (0.86–2.88) was positively associated with RCC in women122. The impact of BMI on 331 
overall survival was also studied in 1,975 patients treated with targeted agents. The authors reported on a 332 
median overall survival of 25.6 months (95%CI 23.2-28.6) in patients with high BMI versus 17.1 months 333 
(95%CI 15.5-18.5) in patients with low BMI (adjusted hazard ratio of 0.84, 95%CI 0.73-0.95)123. 334 
Compared with stable weight, neither steady gain in weight nor weight loss was significantly associated 335 
with risk of RCC121.  336 
 337 
[H3] Hypertension and medications. Higher BMI and hypertension were independently shown to 338 
increase the long-term risk of RCC in men whereas a reduction in blood pressure lowered the risk124. 339 
Aspirin use was found to be associated with an increased RCC risk in one out of five studies125; by contrast, 340 
paracetamol (acetaminophen) exposure showed no increased risk126. The role of phenacetin 341 
(acetophenetidin) exposure has been inconclusive127. Statins were reported to significantly reduce the risk 342 
of RCC in a large analysis (n=483,733), with a 48% risk reduction (adjusted odds ratio 0.52, 95%CI 0.45-343 
0.60)128. However, owing to the sporadic and low frequency nature, current guideline does not support the 344 
role of empiric treatment for prevention of RCC in general population; patients with hereditary syndromes 345 
should be monitored more closely and treated accordingly.  346 
 347 
[H1] Management 348 
For patients with surgically resectable RCC, the standard of care is surgical excision by either partial or 349 
radical nephrectomy with a curative intent. By contrast, those with inoperable or metastatic RCC typically 350 
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undergo systemic treatment with targeted agents and/or immune checkpoint inhibitors. Deciding on which 351 
treatment has been largely guided by various nomograms30. For example, the UCLA Integrated Staging 352 
System (UISS) and Stage Size Grade and Necrosis (SSIGN) score integrate clinical (1997 TNM stage) and 353 
pathological (Fuhrman nuclear grade) information to recommend the length and frequency of clinical 354 
follow-up and the selection of high-risk patients for adjuvant studies129-131. Similarly, key prognostic factors 355 
have been identified, validated and adopted to guide and stratify patients with metastatic RCC for systemic 356 
treatment, including performance status, time from diagnosis to systemic treatment and blood levels of 357 
haemoglobin, neutrophils, platelets, calcium and lactate dehydrogenase99,132,133. 358 
 359 
[H2] Surgery 360 
Surgical treatment of RCC is related to the clinical stage of the disease and to the general condition of the 361 
patient (FIG. 5). Although typically reserved for localized disease, both partial and radical nephrectomy can 362 
also be used with cytoreductive intent in patients with metastatic disease. Indeed, randomized controlled 363 
trials (RCTs) demonstrating the benefit of this approach date from the 1990s, when cytokine-based 364 
therapies dominated the systemic therapy landscape. Furthermore, although most patients included in RCTs 365 
of targeted therapies also underwent cytoreductive nephrectomy, the current role of excision of the primary 366 
tumour in these patients has yet validated . However, according to main international guidelines many 367 
centres in offer cytoreductive nephrectomy if there is a substantial disease volume at the primary site but 368 
only a low burden of metastatic disease134 369 
 370 
[H3] Partial nephrectomy. The goal of partial nephrectomy is to completely remove the primary tumour 371 
while preserving the largest possible amount of healthy renal parenchyma. Partial nephrectomy is indicated 372 
for patient with T1 tumours (according to the Union for International Cancer Control TNM staging system) 373 
[Au:OK?, ok] and a normal contralateral kidney (elective indication). Moreover, partial nephrectomy is 374 
strongly recommended (imperative absolute indications) in patients with RCC who have only one kidney 375 
(anatomically or functionally), in those with bilateral synchronous RCC and in those with von Hippel-376 
Lindau syndrome. Similarly, imperative relative indications include conditions that can impair renal 377 
function (for example, kidney stones, hypertension, diabetes and pyelonephritis). Indeed, partial 378 
nephrectomy offers lower renal function impairment135-137 and equivalent oncological survival outcomes 379 
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compared with radical nephrectomy in those with T1 tumours138,139. More controversial is the favourable 380 
impact of partial nephrectomy on overall survival140,141 because conventional wisdom dictates that removal 381 
of the whole kidney is better in terms of oncological outcome. In this scenario, surgical feasibility remains 382 
the main factor influencing the final decision making process.  383 
  384 
In the past decade, nephrometry scoring systems have been proposed to predict the complexity of the 385 
partial nephrectomy procedure and predict perioperative outcomes according to the anatomical and 386 
topographical tumour characteristics (Table 3)142. The R.E.N.A.L. and PADUA nephrometry systems are 387 
still the most popular and most used tools to preoperatively classify tumours 143. These first-generation 388 
systems, along with the Centrality Index system, mainly factor in tumour-related anatomical parameters, 389 
including face location (that is, anterior or posterior faces, accordingly to their coverage by the anterior or 390 
posterior layers of the renal fascia, respectively), longitudinal polar location, rim location (that is, whether 391 
the tumour is located at the lateral or medial rim of the kidney), degree of tumour extension into the 392 
parenchyma, renal sinus involvement, upper urinary collecting system involvement and clinical maximal 393 
diameter of the tumour. Clinical studies demonstrated that such nephrometry systems were able to predict 394 
the risk of bleeding and post-operative complications in patients who underwent partial nephrectomy 142. 395 
Thus, they represent valid tools for counselling patients and selecting the ideal candidate for partial 396 
nephrectomy according to surgeon experience 143. Second-generation nephrometry systems, such as 397 
Diameter-Axial-Polar system, Zonal NePhRo scoring system and Arterial Based Complexity System, 398 
should be externally validated and tested head-to-head against a first-generation system before being 399 
introduced in the clinical practice.  400 
 401 
Laparoscopic partial nephrectomy (LPN) and robot-assisted partial nephrectomy (RAPN) are the main 402 
alternative to classical open partial nephrectomy (OPN). However, RAPN and OPN are more appropriate in 403 
the treatment of more-complex cases (based on expert opinion). Conversely, LPN should be reserved for 404 
small tumours (usually 4 cm in size) in patients without complex features as defined according to 405 
nephrometry systems (low- or intermediate-risk categories). Available meta-analyses have demonstrated 406 
that RAPN provides equivalent perioperative outcomes to LPN, but a significantly shorter warm ischaemia 407 
time144,145. Moreover, RAPN seems to be significantly better than OPN in terms of perioperative 408 
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complications, estimated blood loss and hospital stay146,147. Conversely, transfusion rate, ischaemia time, 409 
estimated glomerular filtration rate change and early cancer outcomes are similar between the two 410 
approaches147. International guidelines recommended the use of both approaches according to the surgeon 411 
and patient preferences. 412 
 413 
Finally, partial nephrectomy can also involve simple enucleation — entirely sparing the healthy 414 
parenchyma around the tumour. Alternatively, classic enucleoresection whereby a thin layer of healthy 415 
parenchyma is removed or polar or wedge resection whereby a wider excision of healthy parenchyma is 416 
performed are also viable options. A minimal tumour-free surgical margin following partial nephrectomy 417 
seems appropriate to avoid the increased risk of local recurrence24. Positive surgical margins have been 418 
reported in 1-6% of cases regardless the type of used surgical technique148. Haematuria, perirenal 419 
haematoma and urinary fistulas are the most common complications of partial nephrectomy procedures. 420 
Less frequent postoperative complications can be represented by acute renal impairment and infection149. 421 
 422 
[H3] Radical nephrectomy. Classical radical nephrectomy consists in the removal of kidney, perirenal fat 423 
tissue, adrenal gland and regional lymph nodes. However, in patients with tumour ≤5 cm in size, located at 424 
the inferior pole, the adrenal gland can be spared. Similarly, regional lymph nodes dissection can be 425 
reserved for patients with clinically positive nodes detected by CT or during the surgical procedure 150. 426 
Radical nephrectomy can be considered in cases with multiple small renal tumours, in cases in which the 427 
tumour extends into the vasculature and can be a laparoscopic or open procedure (FIG. 6). In most patients 428 
with stage I and II tumours, radical nephrectomy is currently performed using a traditional laparoscopic 429 
approach; the open approach remains the gold standard for the treatment of more complex cases. In 430 
experienced hands, the robot-assisted approach can represent a potential alternative to open surgery in cases 431 
with venous tumour thrombus. 432 
 433 
Data recently extracted from the US National Cancer Data Base support the use of cytoreductive 434 
nephrectomy in those with metastatic disease even while they receive systemic targeted therapies. Indeed, 435 
the median overall survival was 17.1 months in cytoreductive nephrectomy cases versus 7.7 months in non- 436 
cytoreductive nephrectomy group151. 437 
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 438 
  439 
[H2] Active surveillance and ablative therapies  440 
Active surveillance and ablative techniques such as cryotherapy or radiofrequency ablation are alternative 441 
strategies for elderly patients and/or those with competing health risks and limited life expectancy that 442 
renders them unsuitable for surgery15,24. 443 
 444 
A definite protocol for active surveillance has yet to be defined. The most common approach consists of 445 
alternating between ultrasonography imaging and CT or MRI every 3 months in the first year, every 6 446 
months in the second year and annually thereafter. Intervention should be considered for growth to >3-4 cm 447 
or by >0.4-0.5 cm per year152. Data from the Delayed Intervention and Surveillance for Small Renal Masses 448 
(DISSRM) registry in the United States showed that in a well-selected cohort of patients with up to 5 years 449 
of prospective follow-up, active surveillance was not inferior to primary intervention in terms of both 450 
overall survival and cancer-specific survival 26. 451 
 452 
Ablative technology must be able to completely destroy all viable tumour tissue with no area of viable 453 
tumour left. Both cryotherapy and radiofrequency ablation can be performed using a laparoscopic or 454 
percutaneous approach under a CT or ultrasound guidance. A meta-analysis of case series showed 89% and 455 
90% of efficacy for cryoablation and radiofrequency ablation, respectively25; complication rates are 20% 456 
and 19%. Available low quality studies suggest a higher local recurrence rate for ablative therapies 457 
compared with partial nephrectomy153. 458 
 459 
[H2] Medical management 460 
The past 10 years have seen the approval of a number of targeted therapeutic agents and one 461 
immunotherapy agent for the treatment of metastatic RCC (FIG. 7). However, in the adjuvant setting after 462 
surgery, the situation is less clear and a randomised trial (ASSURE) of sunitinib versus sorafenib versus 463 
placebo showed no benefit for either drug therapy in terms of disease-free survival131. Notably, a recent 464 
study in the adjuvant setting reported a disease-free survival benefit for 1 year of sunitinib therapy in 465 
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comparison with observation in the S-TRAC trial130. A number of other trials of adjuvant targeted therapies 466 
(such as PROTECT and SORCE) have completed accrual and will report outcomes in the next 12 months.  467 
 468 
[H3] Targeted therapies. Given the highly vascular nature of RCCs, it is unsurprising that several 469 
therapies are available to exploit this feature. Indeed, tyrosine kinase inhibitors targeting the VEGF 470 
signalling axis approved in the first-line and second-line settings for the treatment of metastatic RCC in 471 
United States and European Union are sorafenib, sunitinib, pazopanib, axitinib, lenvatinib and 472 
cabozantinib154-159. All approvals have been as single agents except the combinations of lenvatinib with 473 
everolimus; additionally, the anti-VEGF monoclonal antibody bevacizumab is approved for use with 474 
interferon-α160,161. Broadly speaking, sunitinib, pazopanib and the combination of bevacizumab and 475 
interferon-α are approved as first-line options whereas axitinib and cabozantinib are approved in the second 476 
line. The mTOR inhibitors everolimus and temsirolimus are approved as single agents in the second-line 477 
setting and in the first line in patients with poor risk status162,163. Indeed, arguably the landmark trial of 478 
first-line systemic therapy of metastatic RCC was the phase 3 study of sunitinib versus interferon-α 479 
reported in 2007 in which the superiority of sunitinib in terms of response rate, progression free and overall 480 
survival was reported155. This trial established sunitinib as the standard of care and the drug remains the 481 
comparator for all currently recruiting phase 3 studies of new drugs. 482 
 483 
No clinically usable markers are available to select patients for particular therapies, despite intensive 484 
efforts. As such, the average duration of disease control with these drugs is 8-9 months in the first line 485 
setting and 5-6 months in the second line setting. Most of the phase 3 RCTs leading to the approval of these 486 
agents have excluded patients with nccRCC (Box 1) and as such this evidence base relates largely to 487 
ccRCC. Furthermore all of these agents are given continuously until disease progression in the absence of 488 
major toxicity. Furthermore, alternative schedules such as those electively interrupting therapy for 489 
prolonged periods have not been reported from RCTs. 490 
 491 
[H3] Immunotherapy. Cytokines such as interferon-α and high dose IL-2 that enhance anti-tumour 492 
immune activity have been used since the 1990s to treat metastatic RCC and were standards of care prior to 493 
the introduction of sunitinib164. Both drugs typically benefit only a small subset of patients (generally those 494 
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with intrinsically favourable disease biology) and are associated with significant toxicity, particularly in the 495 
case of high-dose IL-2. Many studies are currently investigating combinations of anti-VEGF therapy with 496 
new-generation of immunotherapy agents in the form of T-cell immune checkpoint inhibitors such as the 497 
antibodies against programmed cell death protein 1 ligand 1 (PDL1), which include avelumab and 498 
atezolizumab, and antibodies against programmed cell death protein 1 (PD1), which include nivolumab and 499 
pembrolizumab). PD1 negatively regulates T cell function and its ligand PDL1 is highly expressed by 500 
cancer cells; accordingly, blockade of the PD1–PDL1 axis promotes T cell activation and immune killing 501 
of the cancer. Another combination under investigation (Checkmate 214, NCT02231749) is nivolumab 502 
with ipilimumab, an inhibitor of the T-cell checkpoint cytotoxic T-lymphocyte-associated protein 4 503 
(CTLA-4). CTLA-4 also downregulates T cell function; its inhibition by these antibodies promotes T cell 504 
activation.  505 
 506 
Nivolumab was approved in United States and European Union after the Checkmate 025 RCT showed an 507 
overall survival benefit compared with everolimus in patients who had failed prior therapy with sunitinib 508 
and pazopanib165. However, the response rate to nivolumab was only 25% (5% for everolimus) and most 509 
patients treated did not experience significant tumour shrinkage. Although these check point inhibitors 510 
show promise, predicting response is difficult. In Checkmate 025, for example, PDL1 expression did not 511 
correlate with response, as had been reported in other trials in other cancer types 165. The reason for this 512 
observation is unknown, but PD-L1 expression is dynamic in space and time and archival (paraffin-513 
embedded) material from the primary tumour used in Checkmate 025 might not have been representative of 514 
PD-L1 expression at metastatic tumour sites.  515 
 516 
Finally, nivolumab is well tolerated compared with everolimus. Furthermore, it has been possible to 517 
combine nivolumab (and other anti-PD1 or anti-PDL1 therapies) with ‘clean’ (that is, more-specific, less-518 
toxic and easier to combine) anti-VEGF therapies such as axitinib and bevacizumab, leading to a number of 519 
phase 3 studies of such combinations in metastatic RCC. 520 
 521 
[H1] Quality of life 522 
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Quality of life and patient reported outcomes have become an important way to assess therapeutic strategies 523 
in the treatment of patients with RCC. Adverse events are important to consider and these are summarized 524 
in Table 4. Although oncological outcomes such as survival are more objective, validated quality of life 525 
measures have been developed to help assess the patient experience. 526 
 527 
For localized RCC, a systematic review was performed which included data from 29 studies that included 528 
randomized and non-randomized studies149. It noted that quality of life outcomes after partial nephrectomy 529 
were superior to those of radical nephrectomy regardless of approach or technique. Interestingly, no good 530 
evidence suggested that cryotherapy or radiofrequency ablation had better quality of life outcomes 531 
compared to nephrectomy. 532 
 533 
For metastatic RCC, quality of life measures become more important as treatment is usually palliative and 534 
patients continually balance quality versus quantity of life. A validated 15-question tool called the 535 
Functional Assessment of Cancer Therapy (FACT)–Kidney Cancer Symptom Index (FKSI) is the most 536 
specific to kidney cancer 166. A subscale of this, the FKSI-DRS (disease-related symptoms) has nine kidney 537 
cancer-specific questions on the topics of lack of energy, pain, weight loss, bone pain, fatigue, shortness of 538 
breath, cough, fever and haematuria. Other more-general questionnaires exist and have been used in RCC 539 
clinical trials, including the Functional Assessment of Cancer Therapy General (FACT-G), the EuroQOL 540 
EQ-5D and Visual Analogue Scale (VAS)167. These tools enable investigators to assess quality of life; 541 
however, limitations including questionnaire burden, incomplete answering and defining a truly clinically 542 
significant minimal difference in quality of life scores remain. 543 
 544 
In the phase 3 registration trial of first-line sunitinib versus interferon- in the metastatic setting, the FKSI, 545 
FKSI-DRS, FACT-G, EQ-5D and EQ-VAS demonstrated a consistent favourable difference in quality of 546 
life for sunitinib 155. This finding can probably be attributed to the favourable adverse effect profile of 547 
sunitinib, which is associated with less fatigue than interferon-, and higher efficacy of sunitinib (31% 548 
response rate) compared with interferon-α (6%). 549 
 550 
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Quality of life was assessed with FKSI-19, the Functional Assessment of Chronic Illness Therapy-Fatigue 551 
(FACIT-F), Cancer Therapy Satisfaction Questionnaire (CTSQ) and Seville Quality of Life Questionnaire 552 
(SQLQ) in the COMPARZ clinical trial comparing first line sunitinib versus pazopanib156. Measurements 553 
were taken at baseline and at day 28 of each treatment cycle, which is typically the point of highest 554 
sunitinib toxicity (including soreness in mouth, throat, hands and feet). Improved quality of life scores were 555 
observed in those patients taking pazopanib versus those taking sunitinib. 556 
 557 
The immune checkpoint inhibitors have also had quality of life analyses reported167. In the Checkmate 025 558 
study of nivolumab used the FKSI-DRS score, these were performed at baseline and every 4 weeks up to 559 
study week 104 after which assessments were reduced. Median time to health-related quality of life 560 
improvement was shorter in patients given nivolumab (4.7 months, 95% CI 3.7–7.5) than in patients given 561 
everolimus (median not reached). The overall survival of patients was longer in those who had high 562 
baseline health-related quality of life scores who then improved than those with similar baseline whose 563 
scores then deteriorated. The shortest overall survival was observed in those with low baseline scores who 564 
then deteriorated. 565 
 566 
[H1] Outlook 567 
With the considerable advances in the molecular biology and management of RCC over the past several 568 
decades, it is not without reason that one could describe the current era of knowledge and available 569 
treatments as the ‘golden age’ of research. If we are to progress further, advances in diagnosis, local 570 
management and systemic therapy are needed to achieve >80% long-term survival that might define the 571 
future ‘diamond age’ of kidney cancer research and therapy (FIG. 7). Areas that currently show promise 572 
include developing strategies for treating high-risk patients, biomarkers to guide treatment and preventing 573 
and overcoming drug resistance.  574 
 575 
[H2] Biomarkers to guide treatment 576 
Although wide ranging clinical outcomes can be attributed to tumour heterogeneity in RCC, opportunities 577 
to further improve clinical outcomes on the basis of individual tumour characteristics (so called precision 578 
medicine) is an emerging field. Given that nivolumab, cabozantinib and lenvatinib were only recently 579 
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approved, and few correlative studies have been reported, potential biomarkers for VEGF and mTOR 580 
inhibitors currently have the most promise.  581 
 582 
Biomarkers can range from clinical parameters (such as blood pressure) and endogenous substances (such 583 
as plasma proteins) to pathobiological features specific to individual tumours (such as mutations). For 584 
example, as an on-target clinical biomarker, hypertension (systolic blood pressure ≥140mmHg) in patients 585 
receiving VEGF inhibitors has been shown to be associated with longer progression free survival and 586 
overall survival168. Additionally, many studies have looked into circulating biomarkers169, among which 587 
high levels of IL-6, IL-8, hepatocyte growth factor and osteopontin were associated with shorter 588 
progression free survival in patients receiving pazopanib and sunitinib170,171 whereas high levels of lactate 589 
dehydrogenase were associated with better overall survival in those receiving temsirolimus but not 590 
interferon-α172.  591 
 592 
Genetic biomarkers are also beginning to be studied for associations with treatment outcome in various 593 
metastatic settings173-175. For example, RECORD-3, a large randomized phase 2 trial (n=471), demonstrated 594 
the better first-line efficacy of sunitinib (progression free survival of 10.7 months) over first-line 595 
everolimus (progression free survival of 7.9 months)22. Interestingly, genomic biomarker analysis of 596 
patients enrolled in RECORD-3 showed that BAP1 mutations were associated with 8.1 month progression 597 
free survival with first line sunitinib but 5.5 month with first-line everolimus — a significant difference. By 598 
contrast PBRM1 mutations showed no such association20, which is consistent with a VEGF inhibitor outlier 599 
study173 and warrants further validation. That BAP1 mutations were associated with inferior outcomes on 600 
everolimus20 is surprising given their reported higher mTORC1 activity than PBMR1 mutant tumours70. 601 
Furthermore, patients with KDM5C mutations were associated with a much longer first-line progression-602 
free survival with sunitinib (20.6 months) than everolimus (9.8 months)20. As mutual exclusivity was 603 
detected between mutations of BAP1 and PBRM1 or KDM5C20, molecular subgrouping of metastatic 604 
ccRCC based on these three genes could be of clinical value in the future. In addition, case-based mTOR 605 
inhibitor outlier studies recognized activation mutations of MTOR and bi-allelic inactivation of TSC1 or 606 
TSC2 as potential biomarkers for long-term responders69,73,75,76. 607 
 608 
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[H2] Managing high-risk patients 609 
A significant number (~30%) of patients with non-metastatic disease (based on clinical and pathological 610 
evaluation at the initial diagnosis) have occult metastases that will eventually become clinically evident. 611 
How to identify and better manage these high-risk patients presents a major challenge for operating 612 
urologists. As we begin to appreciate the impact that prevalent RCC mutations (in PBRM1, SETD2, BAP1, 613 
KDM5C, PTEN, and TP53) have on clinical outcomes, incorporating specific mutational information into 614 
prognostic nomograms will become increasingly useful. For example, transcription signatures such as 615 
ClearCode3486, and other biomarkers in the blood and urine, might be incorporated into validated 616 
predictive biomarkers for RCC recurrence after surgery. Similarly, predicting treatment response to 617 
systemic therapy might be plausible and will reduce cost and improve RCC cancer patient care. Our 618 
improving ability to identify high-risk patients with RCC and formulate personalized treatment and follow-619 
up plans based on multi-omics holds the promise to quickly reduce the incidence of patients developing 620 
overt metastatic disease and render long-term survival.  621 
 622 
[H2] Emerging therapies and changes to treatment 623 
Several promising new drugs with novel mechanisms of action are in various stages of clinical trials. For 624 
immunotherapeutics, ipilimumab, an anti-CTLA-4 antibody, in combination with nivolumab has shown 625 
remarkable response rate of ~40% in the Checkmate 016 trial176. Additionally, the efficacy of autologous 626 
dendritic cell-based immunotherapy, which consists of expanding patient’s own dendritic cells in vitro 627 
followed by the introduction of tumour RNA before re-infusion back to the patient, in combination with 628 
sunitinib has been examined and showed early promise177.  629 
 630 
In the realm of targeted therapeutics, inhibitors specifically targeting HIF-2 have been developed178,179. As 631 
kidney cancer is characterized by aberrant glycolysis (with aberrant glutamine and tryptophan 632 
metabolism65,180,181), it is of interest to learn if the glutaminase inhibitor CB-839182 and the indolemaine-633 
2,3-dioxygenase inhibitor INCB024360183 could yield additional clinical benefits when added to existing 634 
therapies. Finally, as many of these novel therapeutic agents act on modulating the anti-cancer response in 635 
patients, further understanding of the intricate relationship between individual an kidney cancer cell and its 636 
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respective immune microenvironment would be critical for the future success in designing combination 637 
treatment to improve survival87,184-187.  638 
 639 
Given the increasing understanding of tumour biology and the increasing number of treatment options, how 640 
treatments are selected in the future will undoubtedly change (FIG. 8). As well as those already discussed, 641 
potential measures of high values personalized vaccination188, targeted radiotherapy to enhance anti-tumour 642 
immune response189 and selective cytoreductive nephrectomy in patients who were initially inoperable but 643 
later showed marked shrinkage of tumours after systemic treatments. Additionally, neoadjuvant or 644 
adjuvant190 immunotherapy or targeted therapy could become integrated into the current treatment 645 
algorithms.  646 
 647 
[H2] Preventing and overcoming drug resistance  648 
Model systems and clinical experience have shown that inhibiting RCC activity with multiple drugs 649 
specific to different targets is superior to single-agent approaches23,191,192. However, such approaches tend 650 
to produce more toxicities — on and off-target. For example, the combination of sunitinib and everolimus 651 
in treating metastatic RCC subjected patients to severe toxicity193. Nevertheless, bevacizumab, a more 652 
tolerable VEGF pathway inhibitor than sunitinib, plus everolimus is well tolerated and has been shown to 653 
be efficacious in treating nccRCC with papillary features194. The success of polypharmacy relies on 654 
efficient and correct targeting of both primary and secondary (bypass) pathways69,195. In ccRCC, VEGF is 655 
the primary pathway due to the universal VHL loss; secondary targets can include mTORC1, MET and IL-8 656 
but not EGFR or PI3K pathways when one takes into consideration of available clinical158,159,169,196,197 and 657 
preclinical studies92,198-200.  658 
 659 
Given the availability of targeted therapies (FIG. 7), immediate challenge is to design the most effective 660 
and specific regimen through combining or sequencing drugs to prevent resistance in individual patients201. 661 
Interestingly, a recent study in melanoma patients who relapsed after the initial treatment response on PD-1 662 
blockade revealed invaluable insights on how tumour cells might develop resistance to immunotherapies, 663 
including defects in interferon-receptor signalling and in antigen presentation 202. As immune checkpoint 664 
inhibitors functions independently of specific oncogenic pathways and incur distinct resistance 665 
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mechanisms202, the combination of these drugs with targeted therapies is of great clinical interests203 and 666 
theoretically can prevent the emergence of escape mechanisms from either agent. 667 
 668 
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Display items 693 
Box 1 | Limitations in the management of nccRCC.  694 
From the perspective of surgical management, the presence of non-clear cell histology rarely has a bearing 695 
on treatment and, in fact, histological subtype is often unknown pre-operatively. Limited data are available 696 
to guide medical management of non-clear cell renal cell carcinoma (nccRCC) as a consequence of the 697 
exclusion in general of non-clear cell histologies from registration trials of targeted agents over the past 10 698 
years. Importantly, the tumours classed as nccRCC are fundamentally different; there is no reason to 699 
suppose that a therapy effective for papillary RCC would be effective for chromophobe or indeed any other 700 
subtype of kidney cancer. Nevertheless, some trials have been carried out and have broadly established 701 
sunitinib as a reasonable first line option in nccRCC, although the efficacy is less than for clear cell renal 702 
carcinoma (ccRCC). Most patients with metastatic nccRCC are treated with targeted agents approved for 703 
ccRCC, with the data favouring VEGF inhibitors over mTORC1 inhibitors204,22,205. Unfortunately, most 704 
patients with nccRCC succumb to their diseases within 18 months despite systemic treatment12,13,204,205,206, 705 
and currently there is no evidence base for the treatment of nccRCC with checkpoint inhibitors. 706 
Encouragingly, a recent phase 2 trial reported everolimus plus bevacizumab as an effective combination in 707 
treating nccRCC in patients whose tumours display papillary features, achieving an overall response rate at 708 
43% and a median progression free survival at 12.9 months194. Arguably, everolimus plus bevacizumab 709 
should be considered as the comparison arm in trials in rare RCC subtypes displaying predominant 710 
papillary morphology (papillary RCC type I and type II, and unclassified RCC with papillary features). 711 
Overall, the advances made are encouraging, but drug therapies tailored specifically to subtype remains an 712 
unmet need. Initiatives such as rarekidneycancer.org set up by experts and patient advocates are important 713 
steps to encourage rapid communication among patients with rare kidney cancer, doctors specialized in 714 
nccRCC and trialists.  715 
 716 
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Figure 1. Distinct subtypes of RCC. Approximately 75% of renal cell carcinomas (RCCs) are a | clear cell 718 
RCC (ccRCC). b | Papillary RCCs make up ~15% of all kidney cancers and are divided into two types 719 
based on staining features: b | type 1 (basophilic) and c | type 2 (eosinophilic). d | Chromophobe RCCs 720 
make up ~5% of kidney tumours. Other minor subtypes include e | MiT family translocation RCCs and f | 721 
collecting duct RCCs. Additional minor subtypes include medullary RCC, clear cell papillary RCC, 722 
acquired cystic disease-associated RCC, tubulocystic RCC, mucinous tubular and spindle RCC, succinate 723 
dehydrogenase-deficient RCC, hereditary leiomyomatosis, renal cell carcinoma-associated RCC and 724 
oncocytoma. Tumours not fitting into any of these categories are designated unclassified RCC. Scale bar = 725 
200 m.  726 
 727 
  728 
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Figure 2. Globalkidney cancer incidence. Estimated age-standardized rates (ASRs) of incidence for both 729 
sexes (per 100,000 persons) in 2012. Rates are generally higher in developed countries, with the highest 730 
incidence the Czech Republic (reasons unknown). Data from GLOBOCAN database; 731 
http://globocan.iarc.fr.  732 
 733 
 734 
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Figure 3. VHL inactivation in ccRCC and its implication in targeted therapy. Loss of VHL is the most 736 
frequent genetic feature of clear cell renal cell carcinoma (ccRCC). Its loss relieves the cell of negative 737 
regulation of the hypoxia inducible factors (HIFs), which results in increase HIF target gene expression and 738 
ensuing changes in cellular metabolism and signalling that enhances cell survival. For example, increased 739 
vascular endothelial growth factor (VEGF) expression increases angiogenesis in concert with increased 740 
signalling from growth factor receptors in endothelial cells in the tumour microenvironment (including 741 
fibroblast growth factor (FGF) and hepatocyte growth factor (HGF)). Collectively, these changes provide 742 
the targets for therapeutic agents to impede tumour growth, as indicated. FGFR, FGF receptor VEGFR, 743 
VEGF; TSC, tuberous sclerosis complex; PI3K, phosphatidylinositol 4,5-bisphosphate 3-kinase; AKT, 744 
RAC- serine/threonine-protein kinase; Rheb, GTP-binding protein Rheb; mTORC1, mTOR complex 1; 745 
mTORC2, mTOR complex 2; S6K1, ribosomal protein S6 kinase; 4EBP1, eukaryotic translation initiation 746 
factor 4E-binding protein 1; HRE, HIF response element; MET, hepatocyte growth factor receptor.  747 
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Figure 4. Cancer evolution and tumour heterogeneity in ccRCC. Although VHL mutation and 3p loss of 750 
heterozygosity are early events that are evident in all clear cell renal cell carcinoma (ccRCC) cells 751 
regardless of the region of the tumour sampled, common driver mutations (for example, SETD2, MTOR 752 
and KDM5C mutations) are present heterogeneously — suggestive of subclonal evolution of the tumour. a | 753 
Cancer subclones originate from the most recent common ancestor cell (MRCA) in which a normal cell 754 
acquires all functional capacities to become cancer cell. b | Genomic heterogeneity can result from the 755 
sequential, parallel accumulation of mutations, contributing to the heterogeneity and the evolution of 756 
ccRCC. In this example, ‘R’ represents the genomic characteristics of the primary tumour and ‘M’ 757 
represents the genomic characteristics of the metastatic sites, numbered accordingly. The major genetic 758 
lesions acquired after VHL mutation feature in different samples and are indicated on the branches. c | 759 
However, some evidence suggests that tumours can converge by way of parallel evolution. Here, a 760 
hypothetical beaded river model depicts the sequential convergence of SETD2 and KDM5C mutations 761 
through different spatiotemporally distinct genetic events.  762 
 763 
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Figure 5. Stages of kidney cancer and recommended treatments. Staging renal cell carcinoma (RCC) is 766 
based on size, position and lymph node involvement15. For example, a stage I or II tumour is enclosed 767 
wholly in the kidney. Stage III tumours can extend into major veins or adrenal glands within Gerota’s 768 
fascia (the layer of connective tissue encapsulating the kidneys and adrenal glands) or can involve one 769 
regional lymph node involvement. Stage IV tumours can invade beyond Gerota’s fascia and/or have distant 770 
metastases. *Until the introduction of newer targeted therapies beginning in 2005, the 5-year survival of 771 
stage IV RCC was <10%. Treatment is largely guided by stage15,24. For example, those with stage I RCC 772 
who are fit for surgery are recommended partial nephrectomy. However, radical nephrectomy is also an 773 
option; for elderly patients or those who cannot undergo surgery owing to comorbidities, active 774 
surveillance or ablative therapies are recommended. In patients with stage III RCC, radical nephrectomy is 775 
recommended with lymph node dissection in those with clinical enlarged lymph nodes, but systemic 776 
therapies might be the only available option for those with extensive disease and poor performance status.  777 
 778 
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Figure 6. Indications for radical nephrectomy. a | Radical nephrectomy could be considered in cases 781 
with multiple small renal tumours (circled). b | Conversely, radical nephrectomy and contextual excision of 782 
neoplastic thrombus into renal vein or cava vein tumour thrombus is the gold standard treatment for 783 
patients with venous involvement.  784 
 785 
 786 
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Figure 7. Therapeutic evolution and survival outcome of metastatic ccRCC through the four 788 
different eras. a | Prior to 2004, two drugs were available to treat RCC (with a median survival of ~15 789 
months). This so-called dark age of treatments was followed by the modern age (2005-2014), which saw 790 
seven additional regimens gain approval (increasing median survival to ~30 months). Currently, the golden 791 
age has already witnessed the introduction of three drugs, with more anticipated over the next decade. b | 792 
These advances promise to be translated to a significant number of patients (~50%) achieving durable 793 
remissions under active surveillance by 2025 with a median survival of ~5 years. The ultimate goal is the 794 
future diamond age of drug approvals is >80% of patients with metastatic ccRCC long-term survival. 795 
Dashed lines represent predicted survival. 796 
 797 
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Figure 8. Treatment algorithms for renal cell carcinoma. Given the advances in renal cell carcinoma 800 
(RCC) research, how patients are treated — based on their individual tumour characteristics — will likely 801 
change in the future.  802 
 803 
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Table 1. Non-clear-cell renal cell carcinomas 806 
 807 
Tumour 
type 
Subtype Cytogenetic 
alterations 
Genes mutated Gross appearance Histological features* 
Papillary Type 1 Gains of 7, 8q, 12q, 
16p, 
17, 20, and loss of 
9p   
MET   Mixed cystic/solid 
consistency 
 Often whitish in 
colour and may 
display 
haemorrhage and 
necrosis 
 Frequently with a 
well-demarcated 
pseudocapsule 
 Single layer of cuboid 
tumour cells 
 Thin, basophilic papillae 
with scant pale cytoplasm 
and low nuclear grade  
 Concentric lamellated 
calcifications (psamomma 
bodies)  
 Foamy macrophage 
infiltration 
Type 2 Gains of 8q, 
loss of 1p and 9p 
CDKN2A  
SETD2 
NRF2 
 
 
 Heterogeneous, thick 
papillae and eosinophilic 
cytoplasm, high nuclear 
grade, and 
pseudostratification 
 Concentric lamellated 
calcifications  
 Foamy macrophage 
infiltration 
Chromophob
e  
Classic  Loss of 
chromosomes 1, 2, 
6, 10, 13, 17 and 21  
TP53 
PTEN 
 Large, well- 
circumscribed grey 
to tan-brown 
coloured tumour  
 Occasional central 
scar 
 Tumour cells with 
prominent membrane and 
pale cytoplasm 
 Voluminous cytoplasm 
(cytoplasmic accumulation 
of acid 
mucopolysaccharides)   
Eosinophi
lic 
 Large tumor cells with 
fine eosinophilic granules 
 Distinct cell borders 
 Voluminous cytoplasm 
MiT family 
translocation 
NA Recurrent 
translocations 
involving Xp11.2 
(TFE3) or 
6p21(TFEB) 
TFE3 
TFEB  
 Yellowish tissue  
 Often studded by 
haemorrhage and 
necrosis 
 Papillary or nested 
architecture 
 Abundant clear or 
eosinophilic cytoplasm 
Collecting 
duct 
NA Losses at 8p, 16p, 
1p, 9p, and gains at 
13q 
Unknown  Partially cystic 
 White-grey 
appearance 
 Often exhibit 
invasion into the 
renal sinus 
 Tubulopapillary pattern 
 Often with cells taking 
columnar pattern with 
hobnail appearance 
 Presence of mucinous 
material 
 Desmoplastic stroma 
Medullary  NA Poorly described, 
but thought to be 
normal karyotype 
SMARCB1    Tan/white 
appearance 
 Poorly defined 
 Capsule 
 Extensive 
haemorrhage and 
necrosis 
 Poorly differentiated, 
eosinophilic cells 
 Inflammatory infiltrative 
cells 
 Sheet-like or reticular 
pattern common 
Oncocytoma NA  Loss of 
chromosome 1 
and Y and CCND1 
rearrangement 
Mitochondrial genes 
(COX1, COX2, ND4 
and CYTB) 
 
 Mahogany colour 
 Circumscribed 
 Occasional central 
scar 
 Polygonal cells with 
abundant eosinophilic 
cytoplasm  
  35 
 Rarely with 
necrosis 
 Uniform, round nuclei 
Adapted from Ref. 208. NA, no applicable. *No consensus is currently available describing the immune 808 
infilitration of non-clear-cell renal cell carcinomas.  809 
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Table 2. Hereditary syndromes associated with renal cell carcinoma  811 
Syndrome 
(Phenotype MIM 
reference) 
Gene 
(position) 
Protein Incidenc
e of 
developi
ng 
kidney 
tumour 
(%) 
Median 
age at 
diagnosis 
(years) 
Other phenotypic features   
Clear cell renal cell carcinoma* 
von Hippel Lindau 
disease (193300) 
 
 
VHL (3p25-
26) 
pVHL 25-45 40  Hemangioblastoma 
 Pancreatic neuroendocrine tumours  
 Pheochromocytoma 
 Renal cysts 
 Pancreatic cysts 
 Ovary cystadenoma  
 Epididymal cystadenoma 
BAP1 mutant disease 
(614327)  
 
 
 
BAP1 
(3p21) 
BRCA-
associated 
protein 
No data No data  Breast cancer 
 Uveal melanoma 
 Mesothelioma 
 Other cutaneous melanocytic tumors 
SDH-associated 
kidney 
cancer (185470, 
602413, 602690 and 
115310)  
 
 
SDHB 
(1p36),  
SDHC 
(1q21) and  
SDHD 
(11q23) 
Succinate 
dehydrogenase 
subunits B, C 
and D 
5-15 30  Paraganglioma 
 Carotid body tumors 
 Pheochromocytoma 
 Gastrointestinal stromal tumour GIST 
Papillary renal cell carcinoma 
Hereditary 
leiomyomatosis 
and renal cell cancer 
(150800)‡  
 
 
FH (1q43) Fumarate 
hydratase 
2-21 46  Uterine leiomyosracomas 
 Breast cancer  
 Bladder Cancer 
 Cutaneous leiomyomas 
 Uterine leiomyomas 
Hereditary papillary 
kidney cancer 
(605074)§ 
 
 
MET 
(7q31)  
Hepatocyte 
growth factor 
receptor  
No data <60 No additional features 
 
Multiple tumour types 
Birt-Hogg-Dubé 
syndrome (135150)||  
 
 
FLCN 
(17p11.2) 
Folliculin 34 50  Fibrofolliculomas and trichodiscomas 
 Pulmonary cysts 
 Pneumothorax 
 
Tuberous sclerosis 
complex (191100 and 
191092)¶  
 
 
 
 
 
TSC1 
(9q34) and 
TSC2 
(16p13)   
 
Hamartin and 
tuberin 
2-4 30  Subependymal giant cell astrocytomas  
 Angiomyolipomas 
 Renal cysts 
 Facial angiofibroma  
 Ungal and periungal fibromas  
 Hypomelanotic macule, Forehead 
plaque 
 Cardiac rhabdomyomas 
 Connective tissue nevus 
 
Cowden syndrome 
(multiple 
hamartoma 
syndrome; 158350)#  
 
 
PTEN 
(10q23)  
PTEN 34 40  Breast Cancer 
 Endometrial cancer 
 Thyroid cancer 
 Prostate cancer 
 Macrocephaly 
 Intestinal hamartomatous polyps 
  37 
 Benign skin tumors (multiple 
trichilemmomas, papillomatous 
papules and acral keratoses)  
 Dysplastic gangliocytoma of the 
cerebellum 
Hyperparathyroidis
m jaw tumour 
syndrome 
(145001)** 
 
 
HRPT2 
(1q31)  
Parafibromin No data No data  Parathyroid carcinomas 
 Uterine carcinomas 
 Renal cysts and hamartomas 
 Hyperparathyroidism  
 Parathyroid glands tumours 
 Jaw fibromas 
*Familial clear cell kidney cancer with chromosome 3 translocation is another possible syndrome associated with clear 
cell renal cell carcinoma, but the genetic lesions and associated data are unknown. ‡Papillary renal cell carcinoma type 2. 
§Papillary renal cell carcinoma type 1. ||Hybrid tumours; oncocytomas; and chromophobe, papillary and clear cell renal cell 
carcinomas. ¶Angiomyolipomas, epithelioid angiomyolipomas, renal cysts, oncocytomas and papillary and clear cell renal 
cell carcinomas. #Clear cell, papillary and chromophone renal cell carcinomas. **Mixed tumours (epithelial and connective 
tissue), papillary renal cell carcinomas and nephroblastomas. MIM, Mendelian Inheritance in Man database. 
 812 
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Table 3. Nephrometry scoring systems to predict partial nephrectomy complexity and outcomes. 817 
 818 
Nephrometry system  
 
Parameters included Outcomes prediction External validation 
R.E.N.A.L. nephrometry 
25 
Tumour size 
Exophytic rate  
Polar location 
Renal sinus involvement 
UCS involvement 
Face location  
Blood loss 
Warm ischaemia time 
UCS lesion 
Overall complications 
Functional outcomes 
Benign or malignant tumour 
Tumour grade 
Yes 
PADUA classification 153 Tumour size 
Exophytic rate  
Polar location 
Rim location 
Renal sinus involvement 
UCS involvement 
Face location  
Blood loss 
Ischaemia time 
UCS lesion 
Overall complications 
Functional outcomes 
Yes 
Centrality Index 135 Tumour radius 
Tumour depth (horizontal and 
vertical distances) 
Ischaemia time 
Functional outcomes 
Yes 
Diameter–Axial–Polar 
system 136 
Diameter 
Axial distance 
Polar distance 
Blood loss 
Ischaemia time 
Functional outcomes 
No 
Zonal NePhRo scoring 
system 137 
Nearness 
Physical zone 
Tumour radius 
Organization of the tumour 
Perioperative complications No 
Arterial Based 
Complexity Scoring 
System 138 
Size of the renal arterial branches 
needing to be dissected or 
transected to achieve complete 
excision of the renal tumour 
 
Ischaemia time 
Urinary fistula 
No 
UCS, upper collecting system.   
 819 
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Table 4. Selected adverse events and quality of life of the approved agents  822 
 823 
  824 
Drug Adverse events Improvement in 
quality of life? 
Reference   
Axitinib Hypertension, diarrhoea, 
hypothyroidism and hand–foot 
syndrome 
Yes versus sorafenib 157 
Bevacizumab  Proteinuria, hypertension and bleeding Not reported 160 
Cabozantinib Diarrhoea, hand–foot syndrome, 
hypertension, nausea and 
hypothyroidism 
Not reported  
Everolimus Stomatitis, hypercholesterolaemia, 
hyperglycaemia and pneumonitis 
No versus placebo 209 
Nivolumab Colitis, pneumonitis and 
endocrinopathies 
Yes versus everolimus 165 
Pazopanib Diarrhoea, hypertension, liver function 
test abnormalities and hand–foot 
syndrome 
No versus placebo, 
Yes versus sunitinib 
156 
Sorafenib Hypertension, diarrhea, hand–foot 
syndrome and rash 
Yes versus placebo 154 
Sunitinib Diarrhoea, hand–foot syndrome, 
mucositis and hypertension 
Yes versus IFN 155 
Temsirolimus Stomatitis, hyperglycaemia, 
hypercholesterolaemia and oedema 
Yes versus IFN 210 
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